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In past decades, cancer patient survival has been improved with earlier detection and advancements in therapy.
However, many patients who exhibit no clinical symptoms after frontline therapy subsequently suffer, often many
years later, aggressive tumor recurrence. Cancer recurrence represents a critical clinical challenge in effectively
treating malignancies and for patients’ quality of life. Tumor cell dormancy may help to explain treatment resistance
and recurrence or metastatic reactivation. Understanding the dormant stage of tumor cells may help in discovering
ways to maintain the dormant state or permanently eliminate dormant residual disseminated tumor cells. Over the
past decade, numerous studies indicate that various mechanisms of tumor dormancy exist, including cellular
dormancy (quiescence), angiogenic dormancy, and immunologic dormancy. In this short review, we summarize
recent experimental and clinical evidence for these three mechanisms and other possible tumor microenvironment
mechanisms that may influence tumor dormancy.
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Tumor dormancy is a recognized clinical phenomenon
in which disseminated tumor cells (DTCs) remain oc-
cult, asymptomatic, and undetectable over a prolonged
period of time. Dormancy can occur at the earliest stage
of tumor development but also when remnant tumor
cells escape treatment. Tumor dormancy may contribute
to tumor progression and relapse, either locally or meta-
statically at distant sites, years or decades after treat-
ment. Clinical dormancy is frequently observed in many
types of tumors, such as breast cancer (BC) [1], prostate
cancer (PC) [2,3], melanoma [4,5], and B-cell lymphoma
[6,7]. Dormant cells are characterized by their slow
growth, their ability to escape frontline treatment and
host immunity, and their capability to self-renew. A cli-
nical study showed that non-proliferating cancer cells
could persist during chemotherapy and were detected
more frequently in BC patients with progressive disease
than in patients with primary BC [8].
Three molecular mechanisms involved in tumor dor-
mancy have been identified: cellular dormancy (quiescence* Correspondence: sylin@mdanderson.org
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stated.or mitotic arrest), angiogenic dormancy (limited tumor
size), and immunologic dormancy (immunosurveillance,
balance between clearance and proliferation) (Figure 1).
The mechanisms that regulate the transition between the
dormant and proliferating states are largely unknown. In
addition, no dormancy markers have been well charac-
terized. Here, we review recent findings of relevant genetic
abnormalities, novel discoveries regarding tumor dor-
mancy, and possible mechanistic links. This information
should help in the development of appropriate study
models and improve therapeutic approaches to prevent
disease recurrence.Cellular dormancy
Cellular dormancy is a state in which cells are in a quies-
cent state (the G0 phase). These cells do not enter the
normal proliferating cell cycle. Their growth arrest is re-
versible and under certain conditions, such as induction
by growth factors, cytokines, nutrients, or chemical
agents, the cells can re-enter the cell cycle to proliferate
again. Quiescent normal adult stem cells serve as a
source of self-renewal in the maintenance of multiple
adult epithelial tissues. In contrast, quiescence in a
heterogeneous cancer population likely contributes toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 Mechanisms in tumor dormancy. Tumor dormancy can lead to tumor recurrence locally or to metastasis at a distant site. Dormancy
can be induced by more than one mechanism: cellular dormancy (quiescence), angiogenic dormancy (tumor mass size limit), and immunologic
dormancy (immunosurveillance, balance between proliferation and apoptosis). Others mechanisms, such as epigenetic change, tumor
microenvironment, CSCs, EMT, and miRNA, also may involve in tumor dormancy. A tumor microenvironment that is altered (such as by frontline
treatment) can mediate tumor cell entrance into, maintenance, and exit from dormancy through interaction with cells at niches, such as
endothelial cells, stroma, or immune cells.
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and radiotherapy, leading to disease recurrence [9-11].
In patients with prolonged clinical dormancy, the pre-
sence of dormant cells is often identified by their lack of
the cellular proliferation marker Ki-67 as well as the lack
of apoptotic markers [12-14]. Cellular DNA/RNA content
analysis is commonly used to assess for cells in the G0
phase, as indicated by 2 N DNA ploidy and reduced RNA
content. In contrast, cells in the G1/S/G2 phase exhibit
2 N/4 N DNA and higher RNA content [15].
Several cell cycle regulators are known to directly or
indirectly mediate cell quiescence. The cyclin-dependent
kinase (CDK) inhibitors p27Kip1 and p21 can cooperate
to maintain a balance between hematopoietic stem cell
dormancy and proliferation at certain cell-cell interactions
at tumor microenvironmental niches [16]. For example,
cell adhesion of lymphoma cells to bone marrow (BM)
stromal cells was shown to lead to reversible cell cycle
arrest through upregulation of posttranscriptional levels of
p27Kip1 and p21 through activation of the APC/CDH1
ubiquitin ligase complex [17]. In addition, APC/CDH1 in-
creased the ubiquitination and degradation of Skp2 (part
of the p21 and p27 inhibitor, SCF) and subsequently
reduced the level and ubiquitination and degradation of
p27Kip1, which resulted in cell cycle arrest (Figure 2a).
Besides the APC/CDH1-SKP-p27Kip1/p21 signaling
pathway, the multi-subunit DREAM complex was recentlyindicated as a critical regulator of quiescence. This com-
plex consists of a dimerization partner, a Retinoblastoma
(RB)-like pocket protein (p130, encoded by RB-like 2 or
p107, encoded by RB-like 1), E2F protein, and mutil-
vulval class B protein (MuvB). The MuvB core component
is essential for coordinating cell cycle; it recruits, binds,
and directs key transcription factors to the promoters of
periodic cell cycle genes during various phases of the
cell cycle [18]. During quiescence and with a high
expression level of p130, MuvB binds to p130, E2F, and
the dimerization partner to form the DREAM complex
and repress all cell cycle-dependent expression [18-20]
(Figure 2b). Impairing various components of the DREAM
complex by mutation or RNA interference leads to disrup-
tion of cell cycle-dependent repression of genes, such as
p107/p130 and E2F4/E2F5, during quiescence. The ex-
pression level of p107 is high only in proliferating cells,
but knockdown of p130 results in increased expression of
p107, which results in the formation of a p107-DREAM
complex in quiescent cells. However, p130−/−/p107−/−
mouse embryonic fibroblasts lose the ability to form a
functional DREAM complex and fail to repress E2F-
dependent genes expression during quiescence, causing
cells to re-enter the cell cycle [21]. E2F4−/−/E2F5−/− mouse
embryonic fibroblasts can also re-enter the cell cycle from
quiescence but fail to arrest in the G1 phase when the
CDK inhibitor INK4A is overexpressed [22].
Figure 2 Role of cell cycle regulators in the cellular dormancy
(“intrinsic dormancy”) mechanism. (a) In the “typical” cell cycle
pathway, upregulation of CDK inhibitors, such as p21 and p27, can
inhibit cells from entering the cell cycle by downregulating cyclin/CDK
activation. In this scenario, cells can enter into a quiescent state (G0).
The ubiquitin ligase APC/CDH1 enhances the upregulation of p21/p27
expression by increasing the degradation of Skp2 (one of the units
that constitute SCF, a p21/p27/p57 inhibitor). (b) The DREAM complex
in the quiescent state (G0). MuvB recruits and interacts with p130
(RB-like), E2F4, and dimerization partner (DP), forming the DREAM
complex. DYRK phosphorylates MuvB and activates the DREAM
complex, which triggers cells to become quiescent. DYRK also
stabilizes p27Kip1 through phosphorylation and prevents cells from
moving into the G1 phase by reducing the expression of cyclin D.
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kinase (DYRK), a serine/threonine kinase, maintains
quiescence by activating the DREAM complex. DYRK1A
and DYRK1B contribute to the phosphorylation of the
MuvB subunit LIN52 at serine 28, which promotes inter-
action between the MuvB core and p130-E2F during
quiescence [23]. Knockdown or disruption of DYRK1A
activity leads to reduced levels of MuvB phosphorylation
and assembly of the DREAM complex [23]. DYRK1B
can stabilize p27Kip1 [24] and increase the turnover of
cyclin D isoforms [25], thereby preventing cells from
entering the cell cycle and thus maintaining their quies-
cence (Figure 2b).
In summary, a balance between quiescent DREAM
complex and proliferative complexes, the MuvB-BMYB-
FOXM1 complex and the typical RB-cyclin/CDK-dependent
complex, is critical to maintain quiescence. Modulating
functions of the DREAM complex in synchrony with
anti-proliferative treatments may provide a novel thera-
peutic approach to primary cancer treatment and re-
lapse prevention.Angiogenic dormancy
Once DTCs exit from quiescence and proliferate to reach
a certain tumor mass size that requires more than the
normal tissue vasculature can provide, the tumor mass in-
duces angiogenesis to meet its nutrient demands. How-
ever, some tumor cells lack this angiogenic capacity and
are therefore unable to grow beyond a certain size. These
cells are controlled by a balance between cellular prolifera-
tion and apoptosis and remain clinically undetectable,
resulting in angiogenic dormancy. The transition from a
pre-vascular tumor to a highly vascularized and progres-
sively growing tumor is known as the “angiogenic switch”
[26]. The balance between pro-angiogenic factors (such as
vascular endothelial growth factor (VEGF), platelet-derived
growth factor, fibroblast growth factor, and angiopoietin)
and anti-angiogenic factors (such as thrombospondin
(TSP), endostatin, vasculostatin, and angiostatin) plays a
role in the angiogenic switch of dormant cells (Figure 3).
A recent xenograft model study with U-87 human glio-
blastoma cells in SCID mice indicated that the balance
between pro-angiogenic and anti-angiogenic factors is
associated with the dormancy or aggressiveness of tumor
growth [27]. The “aggressive” clones of U-87 cells
formed larger and vascularized tumor masses, whereas
the “dormant” clones formed smaller and avascular
tumor masses. Compared with aggressive clone tumor
cells, these dormant clones expressed high levels of TSP,
angiomotin, and insulin-like growth factor binding pro-
tein 5 and low levels of endothelial cell-specific marker
1 and epithelial growth factor receptor. In addition, the
dormant clone tumor cells exhibited impaired angio-
genesis and slower invasion.
In a BC xenograft study, heat shock protein 27
(HSP27) was identified as a key player in the balance
between tumor dormancy and outgrowth with the onset
of angiogenesis [28]. Reduced HSP27 protein expression
in angiogenic cancer cells led to a low secretion level of
pro-angiogenic factors (such as VEGF-A, VEGF-C, and
basic fibroblast growth factor), which resulted in poorer
proliferation and migration of cancer cells and effectively
suppressed tumor growth and angiogenesis. In contrast,
overexpression of HSP27 in non-angiogenic cancer cells
promoted tumor growth in vivo. For BC or melanoma
patients, a low expression level of HSP27 protein was
associated with less aggressive tumors and improved
patient survival [28].
Chemokine signaling directs certain tumor cells to spe-
cific organs that provide a supportive microenvironment
with cytokines or chemokines, tumor-derived secreted
factors, and tumor-specific homing-regulated receptors
through cross-talk among metastatic tumor cells, stroma,
and organ-derived cells. This environment determines
whether DTCs survive, proliferate, become dormant, or
undergo apoptotic cell death. This niche may be not
Figure 3 Angiogenic dormancy (“extrinsic dormancy”) at niches. At niches, dormancy can be induced through signaling between DTCs,
endothelial cells, and stroma with both upregulation and downregulation of multiple factors and signaling axes. DTCs enter dormancy with a
vascular structure that is stable and non-angiogenic. In contrast, a sprouting vascular structure triggers tumor cells to exit from dormancy
following an “angiogenic switch” in microenvironment, leading to tumor outgrowth and recurrence or metastasis. BMP, bone morphogenetic
protein; CXCL12, Chemokine (C-X-C motif) ligand 12; EGFR, epithelial growth factor receptors; ESM-1, endothelial specific marker 1; FGF, fibroblast
growth factor; HSP27, heat shock protein 27; IGFBP5, insulin-like growth factor binding protein 5; LTBPs, latent transforming growth factor β
binding protein; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor β; VEGFs, vascular endothelial growth factors.
Wang and Lin Experimental Hematology & Oncology 2013, 2:29 Page 4 of 8
http://www.ehoonline.org/content/2/1/29required for recurrence or metastasis, but they do pro-
mote recurrent and metastatic progression, and support
tumor cell colonization.
Gap junctional intercellular communication between
BC cells and bone marrow (BM) stroma can facilitate BC
dormancy. A subset of BC cells with the properties of dor-
mancy, including chemoresistance, cycling quiescence,
asymmetric division, and highly invasive capability, is res-
ponsible for gap junctional intercellular communication
with BM stroma [29]. Interaction between BM stroma-
derived CXCL12 and BC-expressing CXCR4 or CXCR7
receptors can direct BC cells from circulation into BM
stromal niches, causing BC cells to become quiescent in
the BM stroma [30].
Recently, a unique organotypic microvascular niche
model demonstrated that endothelial-derived TSP-1 and
endothelial-derived perlecan maintain BC cells in a quies-
cent state and suppress tumor growth [31,32]. Other
extracellular matrix molecules, such as laminin, type IV
collagen, and latent transforming growth factor β (TGF-β)
binding protein (LTBP), also contribute to dormant niches
[33]. That study showed that the sprouting of neovas-
culature disrupted vascular homeostasis at dormant
niches, which led to the loss of suppressive signals.
Sequentially, extracellular matrix molecules and growth
factors promote micro-metastatic outgrowth of BC cells.TGF-β/bone morphogenetic protein (BMP) signaling
between bone stromal cells and PC cells at bone niches
also mediates the balance between the dormancy of PC
cells and metastasis [34]. Secreted from bone stromal
cells, BMP7 interacts with the BMP receptor 2 of PC
cells; this interaction activates p38, p21, and NDRG1,
thereby inducing dormancy. In a mouse model, BMP7
injection significantly limited tumor growth, whereas in-
hibition of BMP7 increased bone metastasis. In addition,
in PC patients, upregulation of BMP receptor 2 expres-
sion correlated with the extent that bone was free of
metastasis.
The anti-adhesion matrix component LTBP-2 is also
associated with pre-metastatic niches for dormancy
[33]. Low LTBP-2 expression levels were observed in
nasopharyngeal carcinoma (NPC) cell lines and tumor
samples from NPC patients. Overexpression of LTBP-2
induced dormancy and inhibited NPC cell migration
and angiogenesis through the reduction of VEGF, which
led to attenuated tumor formation. In contrast, inhi-
bition of TGF-β/BMP signaling, such as by overexpression
of Coco (a secreted antagonist of TGF-β ligands), induced
the exit of BC cells from dormancy, specifically in the lung
niches, leading to metastatic outgrowth [35].
Osteopontin (OPN) is involved in leukemic dormancy
in BM niches and in the persistence of minimal residual
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tion, proliferating acute lymphoblastic leukemia blasts
express high levels of OPN receptors, such as VLA-4, and
then specifically adhere to stroma-derived OPN, which is
secreted by osteoblasts at endosteal niches. Acute lympho-
blastic leukemia blasts also secrete OPN into the local
microenvironment. With additional niche-specific micro-
environmental factors in BM, leukemic blasts return to
dormancy, resulting in resistance to chemotherapeutic
agents and eventually tumor recurrence. Neutralization of
OPN triggers dormant cells to re-enter the cell cycle, sen-
sitizing them to chemotherapeutic agents [36].
In summary, in the tumor microenvironment or pre-
metastatic niches, communication between cancer cells
and cells at the niches is critical to the regulation of DTC
dormancy and to the angiogenic switch with neovascular
structure homeostasis. A particular challenge is to develop
appropriate clinical models to identify the biomarkers and
therapeutic targets in angiogenic-dormant tumor cells.
Three-dimensional co-culture systems with tissue-like
morphology may provide the best advantage for investi-
gating the mechanisms of angiogenic dormancy in the
tumor microenvironment [27].Figure 4 Immunologic dormancy (“equilibrium dormancy”) at niches.
equilibrium, or escape. DTCs can enter dormancy during equilibrium states
DCTs changes, allowing dormant cells to escape (this state is called immun
and endothelial cells can secret mitogens, immunosuppressive factors, and
trigger cells to exit from dormancy and lead to recurrence or metastasis. C
Interferon gamma; MDSCs, myeloid-derived suppressor cells; NK, natural kilImmunologic dormancy
Immunity also contributes to tumor dormancy under an
equilibrium condition with immunologic clearance. How
DTCs enter into, maintain, and exit from this immu-
nologic dormancy is poorly understood. Immunity can
control tumor cells through three distinct processes: eli-
mination, equilibrium, and escape (Figure 4). Elimination
functions as an extrinsic tumor suppressor in naïve hosts
in which innate and adaptive immunity work together to
detect and destroy transformed cells before they become
clinically symptomatic. Certain DTC variants may not be
completely eliminated, but their net growth is restricted
by immunity control, resulting in an equilibrium state and
maintenance of tumor cells in dormancy. These DTCs
may induce a host-protective immune response, or their
antigen expression (recognized by adaptive immunity via
T-cell effectors) may be modified to adapt to the host im-
mune system. Over a prolonged period, the constant
interaction of immunity with DTCs may edit the immuno-
genicity of dormant tumor cells, causing them to enter
into an attenuated immunogenic state. This attenuated
state leads to the escape process. The edited DTCs begin
to grow progressively in an immunosuppressive tumorThe immune system can control tumor cells through elimination,
. Over years, environmental factors change or the genomic stability of
osurveillance) and reactivate to grow. At niches, immune cells, stroma,
angiogenic factors that modify the tumor microenvironment and
TL, cytotoxic T-lymphocytes; CXCL10, C-X-C motif chemokine 10; INFγ,
ler; TAMs, tumor-associated macrophages; TREG, regulatory T-cells.
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tectable and lead to tumor recurrence [37-39].
Direct or indirect modulation of the immune system in
the tumor microenvironment can enhance the escape
of tumor cells from dormancy. For example, DTCs can
directly attenuate the cytotoxic T-lymphocyte response by
reducing T-cell activation, promoting DTC resistance
to cytotoxic T-lymphocyte-induced apoptosis, or alte-
ring tumor-associated antigen presentation to antigen-
presenting cells [40,41]. Numerous immune cell types
may enhance indirect escape from dormancy through
their infiltration into the tumor microenvironment;
these cell types include myeloid-derived suppressor
cells, regulatory T-cells, and tumor-associated macro-
phages [27,42,43]. These cells can secret numerous mito-
gens, cytokines, and some angiogenic factors to promote
angiogenesis, cell proliferation, and immunosuppression
[40]. For example, interleukins 23 and 12 were shown to
play critical and opposing roles in immunologic dormancy
in a mouse model of methycholanthrene-induced fibrosar-
coma [44]. Interleukin 23 can suppress both innate and
adaptive anti-tumor effectors responses, whereas inter-
leukin 12 prevents cancer outgrowth [44,45].
Immunologic dormancy may rely on the high genomic
instability of DTCs. Once dormant DTCs accumulate
genomic aberrations years or decades after radiotherapy
or chemotherapy, genomic instability generates a less im-
munogenic phenotype that can better evade anti-tumor
immunity, resulting in reactivation of these cells. Genome
or exome sequencing analysis of unedited and edited
DTCs may reveal mutations involved in the process of exit
from dormancy as a consequence of genomic instability.
Specific mutations in these edited tumor cells may lead to
altered expression of tumor-specific antigens for T-cells,
and these antigens could serve as immunotherapeutic
targets.
Other potential mechanisms in tumor dormancy
Several other mechanisms may play roles in tumor dor-
mancy, such as genetic and epigenetic changes, cancer stem
cells, tumor microenvironment, epithelial-mesenchymal
transition, and non-coding RNA manipulation. Epigenetic
modification by DNA methyltransferase and histone
deacetylase within DTCs may mediate the expression of
genes that trigger cells to enter into, maintain, or exit from
dormancy. For example, altered tumor-associated antigen
expression through epigenetic change in DTCs may lead
to the escape of these cells from immunity and reactivate
their growth. Epigenetic change also may regulate quies-
cence through the nontraditional RB/p27 pathway.
CSCs have similar properties as dormant cells, including
slow growth, escape frontline treatment and host immu-
nity, and capability to self-renew. However, whether can-
cer stem cells involve in tumor dormancy is controversial.One group identified a population of slow-cycling BC cells
with retained metabolism labeling. These cells exhibited
increasing capability of chemotherapy resistance and lead-
ing to tumor recurrence in CSC-independent model [46].
In contrast, one subset of BC with CSC marker (Oct4hi/
CD44hi/med/CD24−/+) and properties can facilitate dor-
mancy in pre-metastatic niches [29]. Prostate CSCs with
senescence reversibility in BMP7-dependent manner con-
tribute dormancy in bone [27].
Stress signaling or suppressive signals in the tumor
microenvironment may reverse the epithelial-mesenchymal
transition in tumor cells and induce tumor cells into dor-
mancy or quiescence. However, a subsequent angiogenic
switch or altered immunity eventually reactivates dormant
tumor cells, resulting in tumor recurrence. Tumor micro-
environment also facilitates a switch between proliferation
and dormancy by the balance between two mitogen-
activated protein kinase (MAPK) signaling pathways, the
extracellular signal-regulated kinase (ERK) and p38 signa-
ling pathways [47-50]. Angiogenesis-associated mitogen-
activated protein kinase (uPAR) functions as a central
regulator of the ratio of ERK/p38. Loss of uPAR signaling
from tumor microenvironment results in stress signaling
with low ERK and high p38 activities, which in turn lead
to dormancy. In contrast, tumor microenvironment shift
may lead to reactivate uPAR signaling following high ERK
and low p38 activities, which can reactivate dormant cells,
leading to recurrence and metastasis [51].
Non-coding RNAs were recently identified as potential
biomarkers in human cancers. A single microRNA
(miRNA) molecule can affect the expression of hundreds
of genes and numerous signaling pathways [52,53].
miRNA may affect dormancy through various pathways.
For example, miRNA-190 is upregulated in dormancy-
prone glioblastomas and osteosarcomas, and it mediates
several transcriptional factors, tumor suppressor genes,
and interferon response pathways [27]. In summary, epi-
genetic modification or non-coding RNAs may be able
to regulate dormancy. Epigenetic and non-coding RNA
microarray techniques could help identify potential dor-
mancy regulators and pathways. However, developing
study models and distinguishing between dormant and
heterogeneous tumor populations are complicated and
challenging tasks.
Kim and colleagues recently published a gene signa-
ture for tumor cell dormancy that was based on results
from two clinical studies on tumor cell quiescence or
angiogenic failure [36]. The 49-gene signature they de-
veloped represents a dormancy score, which is based on
upregulated and downregulated genes in dormant cells
[54]. The researchers applied the dormancy score to
human BC samples from four microarray studies and
concluded that estrogen receptor-positive tumors had a
higher dormancy score, which correlated with a low
Wang and Lin Experimental Hematology & Oncology 2013, 2:29 Page 7 of 8
http://www.ehoonline.org/content/2/1/29proportion of metastasis, whereas estrogen receptor-
negative tumor had a lower dormancy score, which corre-
lated with a higher proportion of metastasis. Whether this
gene signature is actually associated with dormancy and
recurrence/metastasis and whether it could serve as a
tumor dormancy biomarker need to be confirmed with an
appropriate dormancy model.
The DNA damage repair response, especially the path-
way that responds to DNA double-strand breaks, may
protect dormant tumor cells from radiotherapy or chemo-
therapy. An example is the non-homologous end joint
(NHEJ) pathway. In this pathway, the broken ends are
directly ligated without the need for a homologous tem-
plate, in contrast to homologous recombination. While
the homologous recombination pathway is error free, the
NHEJ pathway is error prone. As DNA damage accumu-
lates in DTCs following cancer treatment, NHEJ may be
upregulated to repair these damages and allow tumor cells
to survive; however, this pathway also creates genomic in-
stability in the tumor cells. In certain microenvironments,
these genomically unstable DTCs may become dormant,
maintain dormancy, or eventually reactivate, becoming
more aggressive and leading to cancer recurrence. This
idea needs to be tested in vitro and in vivo with an appro-
priate dormancy model.
Conclusion
Several mechanisms and pathways involved in regulating
tumor cell dormancy have recently been identified. How-
ever, most of these mechanisms are not specific to dor-
mancy. In addition, the lack of suitable model systems for
detecting and maintaining the dormant state creates chal-
lenges in designing systematic studies on dormancy either
in vitro or in vivo. Continued investigation and discovery
are needed to identify dormancy signatures and bio-
markers as well as the therapeutic targets and windows
for “secondary” cancer prevention after primary treatment
has failed. Better understanding of tumor cell dormancy
will lead to novel detection techniques in the clinic and
therapeutic options to prevent deadly tumor recurrence
and metastasis.Abbreviations
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